SLC5A2 and hydrops fetalis: The potential benefits of SGLT2 inhibitors for patients with HF have been identified by several randomized clinical trials, such as the DECLARETIMI 588 trial, the CANVAS program, and the EMPA-REG OUTCOME [12, 23].